BIOMAT Database Logo BIOMAT Database Logo

Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients. 2013

A K Le Page, and M M Jager, and J M Iwasenko, and G M Scott, and S Alain, and W D Rawlinson
University of New South Wales Research Laboratories, Randwick, Australia.

Despite advances in the prophylaxis and acute treatment of cytomegalovirus (CMV), it remains an important pathogen affecting the short- and long-term clinical outcome of solid organ transplant. The emergence of CMV resistance in a patient reduces the clinical efficacy of antiviral therapy, complicates therapeutic and clinical management decisions, and in some cases results in loss of the allograft and/or death of the patient. There is increasing use of antiviral prophylaxis after transplant with little expansion in the range of antiviral agents effective in treatment of CMV. Further understanding is needed of the risk factors for development of CMV antiviral resistance and of therapeutic strategies for treating patients infected with resistant viruses. We review the current status of CMV resistance in solid organ transplant recipients, and provide diagnostic and therapeutic suggestions for the clinician in managing antiviral resistance.

UI MeSH Term Description Entries
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D003587 Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS. Herpesvirus 5, Human,Human Herpesvirus 5,Salivary Gland Viruses,HHV 5,Herpesvirus 5 (beta), Human,Cytomegaloviruses,Salivary Gland Virus,Virus, Salivary Gland,Viruses, Salivary Gland
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D016867 Immunocompromised Host A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation. Immunosuppressed Host,Immunocompromised Patient,Host, Immunocompromised,Host, Immunosuppressed,Hosts, Immunocompromised,Hosts, Immunosuppressed,Immunocompromised Hosts,Immunocompromised Patients,Immunosuppressed Hosts,Patient, Immunocompromised,Patients, Immunocompromised
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D019737 Transplants Organs, tissues, or cells taken from the body for grafting into another area of the same body or into another individual. Cell Transplants,Grafts,Organ Grafts,Organ Transplants,Tissue Grafts,Tissue Transplants,Cell Transplant,Graft,Graft, Organ,Graft, Tissue,Grafts, Organ,Grafts, Tissue,Organ Graft,Organ Transplant,Tissue Graft,Tissue Transplant,Transplant,Transplant, Cell,Transplant, Organ,Transplant, Tissue,Transplants, Cell,Transplants, Organ,Transplants, Tissue
D024882 Drug Resistance, Viral The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation. Antiviral Drug Resistance,Antiviral Drug Resistances,Drug Resistances, Viral

Related Publications

A K Le Page, and M M Jager, and J M Iwasenko, and G M Scott, and S Alain, and W D Rawlinson
Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients.
February 2005, Transplantation,
A K Le Page, and M M Jager, and J M Iwasenko, and G M Scott, and S Alain, and W D Rawlinson
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
April 2008, The Cochrane database of systematic reviews,
A K Le Page, and M M Jager, and J M Iwasenko, and G M Scott, and S Alain, and W D Rawlinson
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
October 2005, The Cochrane database of systematic reviews,
A K Le Page, and M M Jager, and J M Iwasenko, and G M Scott, and S Alain, and W D Rawlinson
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
May 2024, The Cochrane database of systematic reviews,
A K Le Page, and M M Jager, and J M Iwasenko, and G M Scott, and S Alain, and W D Rawlinson
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
February 2013, The Cochrane database of systematic reviews,
A K Le Page, and M M Jager, and J M Iwasenko, and G M Scott, and S Alain, and W D Rawlinson
Cytomegalovirus in solid organ transplant recipients.
December 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
A K Le Page, and M M Jager, and J M Iwasenko, and G M Scott, and S Alain, and W D Rawlinson
Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients.
December 2002, Seminars in respiratory infections,
A K Le Page, and M M Jager, and J M Iwasenko, and G M Scott, and S Alain, and W D Rawlinson
Antiviral medications for preventing cytomegalovirus disease (CMV) in solid organ transplant recipients.
March 2013, Nephrology (Carlton, Vic.),
A K Le Page, and M M Jager, and J M Iwasenko, and G M Scott, and S Alain, and W D Rawlinson
Cytomegalovirus antiviral stewardship in solid organ transplant recipients: A new gold standard.
October 2022, Transplant infectious disease : an official journal of the Transplantation Society,
A K Le Page, and M M Jager, and J M Iwasenko, and G M Scott, and S Alain, and W D Rawlinson
Cytomegalovirus prophylaxis in solid organ transplant recipients.
May 1996, Transplantation,
Copied contents to your clipboard!